Niacin/simvastatin

Drug Profile

Niacin/simvastatin

Alternative Names: KS 01 019; Niaspan®/simvastatin; Nicotinic acid/simvastatin; Simcor

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Kos Pharmaceuticals
  • Developer AbbVie
  • Class Antihyperlipidaemics; Naphthalenes; Nicotinic-acids; Peripheral vasodilators; Vitamins
  • Mechanism of Action Cholesterol inhibitors; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Lipid metabolism disorders

Most Recent Events

  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
  • 08 Jun 2011 The FDA announces label changes for simvastatin products in USA
  • 29 Jul 2010 The US FDA approved two new dosage strengths of niacin/simvastatin
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top